November 10th 2020 - Optibrium Enters Cheminformatics Collaboration with MSD
The collaboration will see the integration of Optibrium’s StarDrop™ software as a central component of MSD’s global drug discovery infrastructure
Optibrium™, today announced a collaboration with MSD tradename of Merck & Co., Inc, Kenilworth NJ USA. As part of the collaboration MSD has adopted Optibrium’s StarDrop™ software as a central component of their cheminformatics infrastructure.
The collaboration, between MSD and Optibrium will include integration of StarDrop™ with MSD’s in-house capabilities and the joint development of new tools, to improve cycle times, efficiency and productivity of the drug discovery process.
Read press release.
October 20th 2020 - Optibrium Launches Cerella™, a Novel Artificial Intelligence Platform for Active Learning in Drug Discovery
Cerella™ is proven to accelerate drug discovery and increase confidence in lead optimisation
Optibrium™, today announced the launch of Cerella™, an Artificial Intelligence (AI) software platform for drug discovery that delivers active learning using advanced deep learning methods. Cerella™ leverages the unique Alchemite™ algorithm, which has been demonstrated to extract additional value from drug discovery data to make more accurate predictions, prioritise experimental efforts and increase confidence in decisions. It thereby reduces costs and improves cycle times while targeting high-quality compounds. Read press release.
September 9th 2020 - Peer-reviewed Study by Optibrium Demonstrates the Value of Deep Learning for Imputation of Drug Discovery Data
Collaboration with Constellation Pharmaceuticals highlights the value of deep learning imputation to exploit heterogeneous drug discovery data
Optibrium™, leading providers of software and services for drug discovery, today announced a peer-reviewed publication, ‘Practical Applications of Deep Learning to Impute Heterogeneous Drug Discovery Data’, in the Journal of Chemical Information and Modeling. This paper is testament to the unique ability of the Alchemite™ deep learning algorithm to extract additional value from experimental data in the context of an evolving drug discovery project. In collaboration with the clinical-stage biopharmaceutical company Constellation Pharmaceuticals and technology partner Intellegens, Optibrium’s Augmented Chemistry™ technologies were demonstrated to more accurately guide compound optimisation to target high-quality compounds. Read press release.
July 8th 2020 - Optibrium and North Carolina School of Science and Mathematics mark five years of education collaboration with summer school ‘Computing COVID-19’
Optibrium’s StarDrop™ drug discovery software inspires the next generation of high-school students in their challenge to target COVID-19
Optibrium™, a leading provider of software and services for drug discovery, and the North Carolina School of Science and Mathematics (NCSSM), the states leading high school for science, technology and math education, are celebrating five years of an education support collaboration. Read press release.
May 12th 2020 - Optibrium Adopts Cheminformatics Toolkits From OpenEye Scientific
High performance libraries provide strong foundation for new developments to StarDrop drug discovery software
Optibrium™ and OpenEye Scientific (OpenEye), leading providers of software and services for drug discovery, today announced that StarDrop™, Optibrium’s software for small molecule design, optimisation and data analysis, is now powered by OpenEye Scientific’s cheminformatics toolkits. These industry-leading cheminformatics libraries offer a robust and performance-orientated foundation that ensures StarDrop will further advance its position as a leading computational software suite and meet the demands posed by future drug discovery projects. Read press release.
April 1st 2020 - Optibrium and Intellegens achieve further success in Open Source Malaria initiative with in vitro validation of in silico generated compound
StarDrop™ and Augmented Chemistry™ prove a powerful combination in AI-guided design and validation of novel antimalarial drug candidates
Optibrium™, leading providers of software and services for drug discovery, and Intellegens™, a spin-out from the University of Cambridge with a unique Artificial Intelligence (AI) toolset, today announced they have reached a further significant milestone in their contribution to the Open Source Malaria (OSM) initiative. The team has successfully completed phase 2 of a global challenge aimed at developing and testing novel antimalarial compounds. During this phase, predictive models from phase 1 were combined with generative methods to design novel compounds. The compounds were subsequently validated by testing their activity against the target. Out of four compounds proposed in this phase, only Optibrium/Intellegens’ entry demonstrated potency against the target indicating the powerful combination of StarDrop™, Optibrium’s computational platform for small molecule design and optimisation, with the AI-powered technologies of its Augmented Chemistry™ platform. Read press release.
February 17th 2020 - Optibrium appoints Dr Tim Hohm as Director of Commercial Strategy and Business Development
Tim Hohm to further develop Optibrium’s sales and business strategy for global market expansion
Optibrium™, a developer of software for drug discovery, today announced the appointment of Dr Tim Hohm as Director of Commercial Strategy and Business Development. Tim will be responsible for leading the Company’s commercial strategy and sales processes, with a focus on further expanding Optibrium’s global customer base. In addition to managing existing customer relationships and new business opportunities, Tim’s role will involve market and customer insight in relation to the Company’s StarDrop™ and Augmented Chemistry™ products and services, helping to guide the continued development of Optibrium’s in silico drug discovery technologies and artificial intelligence services. Read press release.
December 3rd 2019 - Optibrium and Intellegens celebrate success in global challenge to find novel antimalarial compounds
Successful models selected by Open Source Malaria consortium will be progressed through to design novel compounds for synthesis and testing
Intellegens, an artificial intelligence start-up, and, Optibrium™, leading providers of software and services for drug discovery, today announced joint success in the Open Source Malaria global initiative aimed at identifying the best predictive models for antimalarial compounds. Together, the companies developed one of the top models, deploying a cutting-edge deep neural network algorithm, Alchemite™, to accurately predict active compounds with novel mechanisms of actions that could be critical to future malaria control and elimination. As one of four prizewinning models selected, the project will now progress through the next phase of the initiative that includes the proposal of new compounds that are predicted to be active, for synthesis and testing against the malaria parasite. Read press release.
November 19th 2019 - Optibrium collaborates with Enamine and BioSolveIT to add REAL Space Search Tool to StarDrop™
New extension enables researchers to explore the REAL Space of 11 billion readily accessible compounds directly from StarDrop
Optibrium™, BioSolveIT™ and Enamine™, leading providers of software and services for drug discovery, today announced a three-way collaboration enabling efficient searches of Enamine’s REAL Space directly from within Optibrium’s StarDrop™ software. This extension to StarDrop is powered by BioSolveIT’s proprietary Feature Trees (FTrees) technology, to search a vast chemical space of over 11 billion readily accessible compounds and identify novel compounds that are similar to a query structure of interest. The resulting chemical structures and data are pre-formatted and ready to evaluate using StarDrop’s comprehensive suite of integrated software for small molecule design, optimisation and data analysis. Read press release.
October 29th 2019 - Optibrium Announce the Release of StarDrop™ 6.6
Optibrium™, a developer of software for drug discovery, today announced the introduction of StarDrop™ 6.6, the latest version of this comprehensive software platform for small molecule design, optimisation and data analysis. The enhanced software will introduce new in silico modelling approaches, ensuring scientists can easily link two- and three-dimensional structural information, identify potential liabilities and design new compounds with the highest chance of success.
StarDrop’s new pKa model, featured in StarDrop’s ADME QSAR module, integrates quantum mechanics and machine learning to make accurate predictions for a wide range of compounds. Rigorously validated, this model shows excellent on external benchmark datasets specifically created to assess pKa prediction methods.
StarDrop 6.6 also includes an extended suite of SeeSAR™ modules that enhance StarDrop’s capabilities for structure-based design. Read press release.
October 10th 2019 - Optibrium introduces Augmented Chemistry™ services to guide successful drug discovery
Optibrium™, a developer of software for drug discovery, today announced the introduction of its Augmented Chemistry™ services, which provide collaborators with novel artificial intelligence technologies to supplement their skills and experience, enabling them to make more effective decisions and advance their drug discovery projects.
In discovery projects, it is important to base decisions on reliable data to avoid wasted effort pursuing incorrectly selected compounds or missing opportunities by inappropriately discarding potentially valuable compounds. Augmented Chemistry™ services are built on a unique deep learning capability for data imputation, Alchemite™, which has been developed in collaboration with Intellegens Limited. Alchemite™ has been demonstrated to outperform traditional predictive models, both in benchmarking studies  and in partnerships with global pharma and biotech research organisations. Read press release.
March 19th 2019 - Optibrium and InfoChem Collaborate on Retrosynthetic Analysis in StarDrop
Optibrium™, a developer of software for drug discovery, today announced a collaboration with InfoChem GmbH, a leader in cheminformatics. The collaboration provides StarDrop™ users with easy access to ICSYNTH light, an entry-level version of InfoChem’s computer-aided synthesis design (CASD) software to generate synthesis pathways for a target molecule. By stimulating new and unbiased ideas, researchers can explore alternative or novel synthetic routes with the potential to save time and reduce costs.
StarDrop can access ICSYNTH light to evaluate possible synthetic pathways for new molecules designed in StarDrop’s interactive designer or Nova module. This provides an invaluable tool for chemists to easily understand the synthetic tractability of proposed new molecules. Read press release.
January 28th 2019 - Optibrium strengthens senior management team with Financial Director appointment
Optibrium™, a developer of software for drug discovery, today announced the appointment of Clare Devlin as Financial Director. The new role supports the company’s sustained rapid growth and ambitious expansion plans, driven by the success of its StarDrop™ software.
As well as managing all financial aspects of the business, Clare will be part of the senior team developing business strategy and objectives. Clare brings a wealth of commercial experience, having held Financial Director roles at Scintacor, Addviso and Genestack, where she developed and implemented effective business strategies. She specialises in business advice, management and financial accounting, business planning, forecasting and restructuring. Read press release.
November 5th 2018 - Optibrium and University of Nottingham Collaborate on Innovative Teaching Programme
Provides students with the opportunity to design new drug-like molecules targeting fibrotic diseases and malaria with cutting-edge drug discovery software
Optibrium™, a developer of software for drug discovery, today announced it had entered into a collaboration with the University of Nottingham, a pioneering research institution and university.
Optibrium’s StarDrop™ software will be available to a number of 4th year MSci Chemistry project students at the University of Nottingham as part of their training in modern drug discovery to aid in the design of potential new candidate compounds for integrin inhibition in fibrotic diseases and malaria, as part of their collaboration with GSK. Read press release.
September 19th 2018 - Novel deep learning drug discovery platform gets £1 million innovation boost
Optibrium™, Intellegens and Medicines Discovery Catapult awarded funding to apply machine learning in drug discovery
Funding to support Artificial Intelligence (AI) in drug discovery takes a significant step forward today as Optibrium, Intellegens, and Medicines Discovery Catapult secure a grant from Innovate UK to fund a £1 million project.
The program will see Optibrium, which creates software to improve the efficiency and productivity of drug discovery, and Intellegens, a spin out from the University of Cambridge which is focused on a specific form of AI called ‘deep learning’, work with Medicines Discovery Catapult over the next two years. Read press release.
September 11th 2018 - Optibrium and Intellegens Collaborate to Apply Novel Deep Learning Methods to Drug Discovery
Partnership combines Intellegens’ proprietary AI technology with Optibrium’s expertise in predictive modelling and compound design
Optibrium™, a developer of software for drug discovery, today announced it had signed a collaboration agreement with Intellegens, a company developing novel artificial intelligence (AI) software. The collaboration will provide Optibrium clients with access to advanced, proprietary deep learning methods that will extend and improve predictive models to guide the more efficient design and selection of high quality drug candidates. Read press release.
September 4th 2018 - Optibrium and Enamine collaboration extends commercial compound database access for StarDrop users
Partnership expands number of free extensions available through StarDrop
EnamineStore contains over 3.3 million screening compounds, and 7.8 million building blocks
Optibrium™, a developer of software for drug discovery, today announced a collaboration with Enamine, a chemical research organisation and compound supplier. The collaboration provides StarDrop™ users with easy access to EnamineStore, a database of their commercially available screening compounds and chemical building blocks. StarDrop has been developed to connect seamlessly with a wide variety of internal and external informatics systems and this latest partnership further extends the wealth of information available to users through StarDrop and its capabilities for small molecule design, optimisation and data analysis in drug discovery. Read press release.
June 19th 2018 - Optibrium Introduces StarDrop 6.5
Novel features include modelling for drug metabolism prediction and virtual library enumeration
Enhanced data visualisation environment for more efficient data analysis and project management
Optibrium™, a developer of software for drug discovery, today announced the launch of version 6.5 of StarDrop™ that provides a complete platform for small molecule design, optimisation and data analysis. The latest release introduces WhichP450, a new feature in StarDrop’s P450 metabolism module that predicts which human Cytochrome P450 enzymes are the major metabolising isoforms for a novel compound. Understanding how a compound is metabolised enables identification and analysis of its potential metabolites, and guides the design of molecules with a reduced risk of drug-drug interactions or variations in exposure across the patient population. Read press release.
January 30th 2018 - Optibrium Expands US and UK Operations
Appoints Dr. Scott Lyon as Director of Business Development located on West Coast, USA
Moves to larger Headquarters in Cambridge, UK
Optibrium™, a developer of software for small molecule drug discovery, today announced it has appointed Dr. Scott Lyon as Director of Business Development and relocated its Headquarters and R&D facilities, to Cambridge Innovation Park, Cambridge, UK. Read press release.
October 10th 2017 - Optibrium Joins EUR 40 Million eTRANSAFE project
Prestigious line-up of pharma, academia and SMEs aim to improve security in drug development process
Optibrium™, a developer of software for small molecule drug discovery, today announced that it will join the Enhancing Translational Safety Assessment through Integrative Knowledge Management (eTRANSAFE) project. eTRANSAFE is a five-year, 40 million EUR European collaboration between private and public organisations which seeks to improve safety assessment across the drug discovery and development process, ultimately with the aim of enabling the delivery of safer medicines. Read press release.
July 25th 2017 - Optibrium and Bugworks Sign Agreement for StarDrop License
Antimicrobial resistance Biopharma selects StarDrop to guide discovery of next generation of antibiotics
Optibrium™, a developer of software for small molecule drug discovery, and Bugworks Research Inc. (Bugworks), a company focused on discovering biopharmaceuticals for the treatment of critical and serious bacterial infections, today announced the signing of a two-year agreement to license Optibrium’s StarDrop™ software. The agreement will see deployment of StarDrop and five of its plug-in modules enabling Bugworks’ scientists at their research site in India to quickly understand structure-activity relationships, identify potential liabilities and design new compounds with the highest chance of success. Read press release.
June 27th 2017 - Optibrium Introduces StarDrop 6.4 with Universal Pose Generation Interface
Adds seamless link to compound structure assessment in 3D docking and alignment models
Optibrium™, a developer of software for small molecule drug discovery, today announced the launch of version 6.4 of the StarDrop™ platform. The latest release includes a universal Pose Generation Interface, which seamlessly links expertly prepared docking and alignment models with StarDrop’s comprehensive environment for small molecule design, optimisation and data analysis. The integration of this 3-dimensional (3D) information with analyses based on 2-dimensional (2D) structure, ensures that scientists can quickly understand structure-activity relationships, identify potential liabilities and design new compounds with the highest chance of success. Read press release.
May 30th 2017 - Optibrium, Imperial College and DNDi Collaborate in Drug Development Programme for Neglected Diseases
Provides MSc students with industry-relevant learning tools and pharma with a new pipeline of candidate compounds
Optibrium™, a developer of software for small molecule design and optimisation today announced it had entered into a collaboration with Imperial College London, the world leading science-based research institution and university, and Drugs for Neglected Diseases initiative (DNDi), a non-profit drug R&D organisation developing new treatments for neglected diseases. Optibrium’s StarDrop software will be available to students at Imperial College studying MSci and MRes programmes in Medicinal Chemistry, as part of a collaborative project with DNDi to design new candidate compounds for Visceral Leishmaniasis. Optibrium will also provide teaching on the application of software for drug discovery to these students. The collaboration is part of DNDi’s Open Synthesis Network, a global health programme focused on neglected diseases, and also supports a wider initiative to provide students the most relevant courses for a career in the pharmaceutical industry. Read press release.
May 9th 2017 - Optibrium and Goldfinch Bio Sign Agreement for StarDrop License
Goldfinch Bio's researchers select StarDrop to guide successful drug discovery
Optibrium™, a developer of software for small molecule discovery, and Goldfinch Bio, a company focused on discovering and developing precision therapies to treat patients with kidney disease, today announced that the company has signed a multi-year agreement to license Optibrium's StarDrop software. The agreement will see the deployment of six of StarDrop's plug-in modules and implementation of StarDrop’s Query Interface for seamless integration with Goldfinch Bio's chemistry and biology databases. Read press release.
April 11th 2017 - Lhasa and Optibrium Enter Research and Product Development Collaboration
Drug discovery software specialists combine expertise to extend studies into drug metabolism modelling
Optibrium™ and Lhasa Limited (Lhasa), developers of software for small molecule property prediction, design and optimisation, announced today they have formed a collaborative partnership to research next generation drug metabolism modelling. Results from the work will be used by both organisations in the development of future products with improved and extended metabolism prediction capabilities. Read press release.
January 31st 2017 - Optibrium Signs Agreement with Zastra Innovations for Distribution in India
New partnership gives researchers improved access to Optibrium’s StarDrop with dedicated local support
Optibrium™ a developer of software for small molecule design and optimisation, announced today that it has appointed Zastra Innovations (Zastra) to be its sole distributor in India for StarDrop™, the company’s flagship product. Zastra will provide researchers in India with the full suite of StarDrop software, combined with local access to expert technical and customer support. Read press release.
January 12th 2017 - Optibrium and eMolecules Collaborate on Chemistry Data Integration in StarDrop
Combines eMolecules’ collection of commercially available chemicals with StarDrop’s data analysis and compound design capabilities in drug discovery
Optibrium™ a developer of software for small molecule design and optimisation today announced a collaboration with eMolecules, the provider of a comprehensive chemical sourcing database. The collaboration provides StarDrop™ users with seamless access to eMolecules’ extensive collection of screening compounds and chemical building blocks, further extending StarDrop’s capabilities to guide compound selection and design. Read press release.
November 30th 2016 - Optibrium and MolPort Collaborate to Improve Speed and Cost-Efficiency of Drug Discovery
Partnership combines MolPort’s 6.3 Million HTS Compounds with StarDrop’s data analysis and compound design capabilities
Optibrium™ a developer of software for small molecule design and optimisation, today announced a collaboration with MolPort, the provider of a comprehensive chemicals database, marketplace and order fulfillment platform. The collaboration offers StarDrop™ users fully integrated access to MolPort’s drug discovery database of 6.3 million commercially available screening compounds and chemical building blocks via its curated collection of catalogues from major chemical suppliers. The latest in a series of recent partnerships with commercial providers, this link with MolPort further extends StarDrop’s capabilities to improve the speed, efficiency, and productivity of the drug discovery process. Read press release.
October 31st 2016 - Optibrium and Collaborative Drug Discovery Partner on Integration of StarDrop with CDD Vault
Collaboration provides a comprehensive platform for data management, analysis and compound design in drug discovery
Optibrium™ and Collaborative Drug Discovery (CDD), developers of software products and services for drug discovery and development, today announced a collaboration to integrate the StarDrop™ and CDD Vault® platforms. This creates a seamless connection in real time between project data, securely held and managed in CDD Vault, and StarDrop's unique compound design and optimisation capabilities. Instant access to the latest assay and compound data, with which a project team can share, interpret and model their chemistry, will lead to better decisions and shorter project timelines. Read press release.
October 13th 2016 - Optibrium Introduces Database Query Interface for StarDrop
Providing instant access to compound data to interpret, model and guide drug discovery decisions
Optibrium™, a developer of software for small molecule drug discovery and optimisation, today announced the commercial launch of a database Query Interface for users of the company's StarDrop software. The new tool provides an adaptable interface between an organisation's own research data management systems and StarDrop's unique compound design and optimisation capabilities. Instant access to the latest data, with which a project team can interpret and model their chemistry, is a key challenge in enabling drug discovery programmes to make effective data-driven decisions. Read press release.
September 20th 2016 - Optibrium and The Edge Collaborate on Integration of StarDrop with BioRails
Combination provides an enterprise platform for comprehensive data management, analysis and compound design in drug discovery
Optibrium™ and The Edge Software Consultancy, developers of software products and services for drug discovery and development, today announced a collaboration to provide an integrated solution linking the StarDrop™ and BioRails™ platforms. The combination provides a seamless drug discovery workflow linking the latest research data directly from the lab through to decision making regarding the next round of synthesis and testing, reducing the time and cost to identify new optimisation strategies and target high quality compounds. Read press release.
May 24th 2016 - Optibrium Signs Agreement for Global License of StarDrop
Optibrium announces that Janssen license StarDrop software
Optibrium™, a developer of software for small molecule discovery, today announced that Janssen Research and Development has signed an agreement to license Optibrium’s StarDrop software. The agreement will provide a global licence for StarDrop and eight of StarDrop’s optional plug-in modules. Read press release.
February 9th 2016 - Optibrium Supports Global Health through Academic and Not-for-Profit Consortium
Access to StarDrop™ will support development of new treatments for neglected diseases via Global Health Programme
Optibrium™, a developer of software for small molecule drug discovery and optimisation, today announced it will make its StarDrop™ technology available to an international consortium of academic and not-for profit organisations. Under the agreement, licensed access to StarDrop software will be provided to support drug discovery projects as part of a global health programme focused on developing new treatments for neglected diseases. Read press release.
November 25th 2015 - BioSolveIT and Optibrium Release First Integrated 2D and 3D Software for Medicinal Chemists
Partnership quickly delivers integrated software that combines 3D structure-based design with ADME predictions to guide high quality compound design
German chemoinformatics specialist BioSolveIT and Optibrium, developer of software for small molecule discovery and optimisation, today announce the release of the first software resulting from their recently-announced collaboration. The newly enhanced version of BioSolveIT's popular SeeSAR software adds an entirely new capability – to predict absorption, distribution, metabolism, and excretion (ADME) properties – seamlessly integrated within SeeSAR's, simple and minimalistic design. This helps medicinal chemists to consider these important properties side-by side with SeeSAR's structure-based design capabilities, thereby guiding the efficient design of potent, high quality drug candidates. Read press release.
October 13th 2015 - BioSolveIT and Optibrium™ Sign Collaboration Agreement
Partnership will deliver a link between 2D and 3D design on medicinal chemists' desktops.
Optibrium, providers of software for compound optimisation, and chemoinformatics specialist BioSolveIT, today announced that they will collaborate to create seamlessly integrated data analysis, visualisation and simulation software for drug research.
The two companies are known for their best-in-class prediction tools for selection and optimisation of potential therapeutics, where it is essential to recognise and resolve potential problems as early as possible. Computer software for 'virtual design' of drug candidate molecules prior to synthesis and testing is ubiquitous in medicinal chemistry and an important time-saver in research. As part of the agreement, both companies will exchange their proprietary technologies; the first phase will incorporate a suite of high-quality predictive models of absorption, distribution, metabolism and excretion (ADME) and physicochemical properties from Optibrium's StarDrop™ platform as an optional feature within BioSolveIT's SeeSAR™ package. This will be followed by the integration of SeeSAR's capabilities to work with 3D structural information into StarDrop's unique environment that guides the design of high quality compounds. Read press release.
September 2nd 2015 - Optibrium™ Appoints Head of North American Operations to Support Growing Demand
Optibrium, a developer of software for small molecule discovery and optimisation, today announced the appointment of Dr Tamsin Mansley in a new role as Head of North American Operations. The appointment marks the opening of Optibrium's new office in Cambridge, MA, USA and represents the next phase in the company's expansion plans and business growth, driven by the rapid adoption of its StarDrop™ software. Read press release.
August 10th 2015 - Optibrium™ and Integrated Chemistry Design Introduce Asteris™ 1.1 with Extended Range of Predictive Models and Enhanced Design Features.
Optibrium and Integrated Chemistry Design, providers of software solutions and services for drug discovery, today announced the release of Asteris 1.1, an updated version of the iPad app that delivers highly intuitive chemistry drawing tools with the most visually informative predictive modelling. The latest version of Asteris combines enhanced chemical drawing tools with new and improved gesture recognition for the touch environment. This includes a new chemistry "groups" panel of commonly used chemistry templates, enabling users to explore a much wider range of chemistry designs more quickly. Instant feedback from Asteris' predictive models, guided by the unique Glowing Molecule™ visualization, has also been extended with the introduction of new predictive models for properties, including drug volume of distribution in human. Read press release.
May 18th 2015 - Optibrium™ donates StarDrop™ to North Carolina School of Science and Mathematics.
Students in Robert Gotwals' medicinal chemistry class at North Carolina School of Science and Mathematics can now predict and test the effectiveness of drug compounds and identify how the drugs are metabolized, thanks to two recent gifts of software licenses. Optibrium's StarDrop software enables students to predict properties for known drugs and then design new compounds based on models that predict the compound's metabolism, whether it could be administered orally or would enter the central nervous system, and many other factors. Cresset has also donated its torch3D module for StarDrop, allowing students to visualize, in three dimensions, where and how new compounds are biologically active. Read the announcement.
April 21st 2015 - Optibrium and Certara Collaborate on Integration of StarDrop and D360.
Optibrium™ and Certara®, developers of software products and services for drug discovery and development, today announced a collaboration to provide their mutual customers with an integrated solution linking Optibrium's StarDrop™ with Certara's D360™ platform. The combination of these two products enables researchers to combine the industry-leading self-service data access and analysis capabilities of D360, with StarDrop's unique, interactive environment that guides compound selection and design decisions in drug discovery, helping project teams to identify high quality compounds more efficiently. Read press release.
April 15th 2015 - Optibrium and ChemAxon Announce Technology
Interface between StarDrop and Plexus facilitates seamless access to both software platforms
Optibrium™ and ChemAxon™, developers of software and cheminformatics solutions for drug discovery, today announced the results of a collaboration to integrate ChemAxon's Plexus™ with Optibrium's StarDrop™ software suite. The integration of these platforms further enables researchers to develop strategies for efficient, high quality compound library design. Read press release.
March 19th 2015 - Optibrium Introduces StarDrop 6.1 with New Strategies for Selection and Optimisation of High Quality Compounds.
Next generation software previews at American Chemical Society's Spring National Meeting
Optibrium™, a developer of software for drug discovery, has announced the launch of version 6.1 of its StarDrop™ platform to guide researchers in the design of high quality compounds in drug discovery, agrochemicals and other chemistry fields. The latest release introduces the Matsy™ technology, based on matched molecular series analysis, which proposes strategies for chemical substitutions to optimise compound activity. Also included is a major upgrade to StarDrop's P450 metabolism module that facilitates the design of compounds with improved metabolic stability, in addition to enhancements to the platform's data analysis and management capabilities. Read press release.
January 15th 2015 - Optibrium and NextMove Software Announce Technology Collaboration.
Automatic application of Matsy method for matched series analysis within StarDrop™ will guide compound optimisation in drug discovery
Optibrium™ and NextMove Software, developers of software and chemoinformatics solutions for drug discovery, today announced an agreement to collaborate on the integration of NextMove Software's Matsy technology with Optibrium's StarDrop software suite. The combination of these technologies will help guide scientists to quickly identify novel compounds based on matched molecular series analysis with a high chance of success for their drug discovery projects. Read press release.
October 15th 2014 - Optibrium Introduces the Latest Release of StarDrop™ Featuring Card View™, a Unique Freeform Environment
StarDrop 6.0 gives researchers the freedom to explore and organise complex project data in a flexible and intuitive way
Optibrium™, a developer of software for drug discovery, today announced the release of version 6.0 of its StarDrop™ software platform. This major new release introduces Card View™, an intuitive and highly flexible environment to view and interact with compound data in the context of discovery projects. Card View provides a unique and highly visual way to interpret data on compounds and their relationships, clearly highlighting the best chemistries and optimisation strategies for drug discovery. The software further extends StarDrop's capabilities to reduce the time and cost associated with delivering high quality drug candidates. Read press release.
August 11th 2014 - Optibrium Launches Sentira™: New Software Application for Compound Data Visualisation
Optibrium™, a developer of software for drug discovery, today announced the launch of Sentira™, a new desktop application that provides dynamic data visualisation and analysis of compound data. Applicable across all fields of chemistry, Sentira enables users to quickly find patterns in compound data, visualise structure-activity relationships (SAR) and elegantly present and report findings. Researchers can intuitively review and interpret compound data sets from large screening libraries to individual chemical series in drug discovery, agrochemical, flavourings, cosmetics, fragrances and other industries.
Available for download from www.sentira-software.com, users can immediately get started with a free 30-day trial. Following this, flexible and cost-effective Sentira licensing options are available, including monthly, annual and perpetual plans. Read press release.
April 29th 2014 - Optibrium Appoints Director of Computational Chemistry as Business Expands
Optibrium™, a developer of software for drug discovery, today announced the appointment of Dr Peter Hunt as Director of Computational Chemistry, as part of further growth across all areas of its business. This success is built on a growing, global customer base for Optibrium's flagship product StarDrop™ within the pharmaceutical industry and its adoption in other chemistry fields including agrochemicals and cosmetics. Optibrium has also recently extended its product portfolio with the introduction of Asteris™, an iPad app that enables researchers to rapidly evaluate new compound ideas when and where they want.
Reflecting the growth in the business, Optibrium has expanded its R&D and operational teams to further accelerate the rate of product innovation and support its rapidly growing customer base. This has required the company to extend its facilities by 50%, less than two years after its last office expansion. Read press release.
March 17th 2014 - Optibrium and Integrated Chemistry Design Collaborate to Introduce Creative Compound Design on iPad®
Optibrium and Integrated Chemistry Design, providers of software solutions and services for drug discovery, today announced the release of Asteris™, a new iPad app that combines highly intuitive chemistry drawing tools with the most visually informative predictive modelling. Asteris enables creative researchers to rapidly evaluate new compound ideas when and where they want, no longer limited to sitting in an office or in front of a computer.Asteris uses Chirys Draw's™ patent pending chemical drawing tools, optimised specifically for the touch environment, allowing users to explore a much wider range of chemistry designs. Instant feedback from StarDrop's™ predictive models, guided by the unique Glowing Molecule™ visualisation, dramatically reduces the time required to identify high quality compound designs. With Asteris users can calculate a range of "core properties", such as logP, molecular weight, polar surface area, and hydrogen bond donors, and predict many ADME properties, including solubility, hERG inhibition, and CNS penetration. Read press release.
January 14th 2014 - Optibrium Announces a New Release of StarDrop, introducing MPO Explorer
Optibrium, a developer of software for drug discovery, today announced the release of a new version of its StarDrop™ software platform. The latest release introduces MPO Explorer™, which provides innovative new methods to guide 'strategic' decisions in research programmes, by helping to identify the key properties and selection criteria with which to identify compounds with a high chance of success. The new module, alongside data visualisation enhancements, further extends StarDrop's capabilities to reduce the time and cost to deliver high quality drug candidates. Read press release.
October 22nd 2013 - Optibrium Launches New Community Website
Optibrium, a developer of software for drug discovery, has launched a new, redesigned community website. Aimed at StarDrop™ and StarVue™ users as well as researchers looking to improve the efficiency and productivity of the drug discovery process, the new site features enhanced content and gives direct access to the Optibrium support team and other users. Regular updates will include new tutorials with video walkthroughs, publications and presentations and free downloads of extensions for StarDrop, all of which have been developed by users, in house or in partnership with expert 3rd parties. The site also offers discussion forums and FAQs to ensure researchers are supported by Optibrium to achieve optimal results from their drug discovery software. Read media alert.
October 8th 2013 - Optibrium Joins Hepatic and Cardiac Toxicity Systems Project and Expands R&D Team
Optibrium, a developer of software for drug discovery, today announced that it will join the HeCaToS (Hepatic and Cardiac Toxicity Systems) project, a major European project with the objective to efficiently investigate the health impact of compounds on the heart and liver. The EU is providing twelve million Euros for the project, which is co-ordinated by Maastricht UMC+. Read press release.
July 2nd 2013 - Optibrium and AstraZeneca Sign Agreement for Global License of StarDrop
Optibrium, a developer of software for drug discovery, today announced that AstraZeneca has signed an agreement to license Optibrium's StarDrop™ software. The agreement will see the global deployment of StarDrop and the ADME-QSAR and Auto-Modeller™ modules to AstraZeneca's researchers. Read press release.
June 11th 2013 - Optibrium Introduces StarDrop 5.4 to Target Novel, Safe and Efficacious Drugs
Optibrium, a developer of software for drug discovery, today announced the release of version 5.4 of its StarDrop™ software platform. This new release offers enhanced features to guide the design of novel, safe and efficacious drugs by providing access to world-leading technologies for toxicity prediction and bioisosteric transformations. These new optional modules further extend StarDrop's capabilities to intuitively target high quality compounds in drug discovery, reducing the time and cost to deliver drug candidates with an improved chance of success. Read press release.
February 5th 2013 - Optibrium and Lhasa Limited Collaborate to Bring High Level, Expert Toxicity Prediction to Chemists' Desktops
Optibrium and Lhasa Limited, providers of software for compound design, selection and property prediction, today announce a technology collaboration agreement. Lhasa's Derek Nexus™ platform for knowledge-based prediction of compound toxicity will be integrated as an optional plug-in module for Optibrium's StarDrop software, that guides the design and selection of high quality compounds in drug discovery. The combination of these technologies will enable chemists to intuitively balance the reduction of toxicity risk with the other requirements for a successful, safe and efficacious drug in hit-to-lead and lead optimisation. An easy-to-use reporting feature will facilitate collaboration between chemists and expert toxicologists to interpret and understand the relevance of a potential liability, enabling effective, early decision-making regarding the prioritisation of chemistries early in the drug discovery process. Read press release.
December 4th 2012 - Optibrium and Digital Chemistry Announce Technology Collaboration to Guide Successful Drug Discovery
Optibrium and Digital Chemistry, providers of software and database solutions for drug discovery, today announce an agreement to collaborate on the integration of Digital Chemistry's unique BIOSTER™ database of precedented bioisostere replacements with Optibrium's StarDrop software suite. This combination will allow drug discovery teams to quickly identify novel, high quality compounds based on the BIOSTER molecular transformations and prioritise these within StarDrop's intuitive environment that guides the design and selection of compounds with an optimal balance of properties. Read press release.
November 20th 2012 - StarDrop 5.3 Offers Intuitive Virtual Library Design
Optibrium, developer of software solutions for drug discovery, today announces a new version of its StarDrop platform. Version 5.3 introduces new features focused on the design of virtual libraries, guided by StarDrop's unique multi-parameter optimisation capabilities to prioritise compounds with the best balance of properties for synthesis and testing. Read press release.
September 3rd 2012 - Optibrium Goes from Strength to Strength as Global Customer Base Continues to Grow
Optibrium, developer of software solutions for drug discovery, today reveals an exciting period of growth across all areas of its business. Optibrium is celebrating significant expansion in its team of experts, requiring relocation to new, larger premises. This success is built on the rapidly expanding, global customer base for Optibrium's primary product, StarDrop. This pioneering drug discovery software platform offers a range of intuitive tools and technologies that guide the selection and design of high quality compounds in drug discovery. Read press release.
June 11th 2012 - Win a Trip to ACS Spring 2013 Meeting & Exposition With Optibrium
Optibrium, developer of software solutions for drug discovery, today announces the launch of its application note competition offering StarDrop users the opportunity to win a trip to the American Chemical Society (ACS) Spring National Meeting & Exposition 2013 in New Orleans, Louisiana. For a chance to win, StarDrop users who use the software in their drug discovery projects are invited to submit an application note demonstrating their innovative use of StarDrop. Optibrium is also providing temporary one-month licences during the competition period to enable those not currently using StarDrop to enter the competition alongside current users. Read press release.
March 21st 2012 - StarDrop 5.2 Adds New FieldAlign Plug-in Module
Optibrium, developer of software solutions for drug discovery, today announces a new version of its StarDrop™ platform. StarDrop 5.2 features a new plug-in module that provides users with access to Cresset's FieldAlign™ technology, which offers a unique, 3-dimensional insight into the biological activity of their compounds. This new development is the first result of the technology exchange, between Optibrium and Cresset, announced earlier this yearand adds another powerful tool to StarDrop that will enable chemists to understand the 3D structure activity relationship (SAR) of their chemistry in order to optimise their compounds. Read press release.
January 4th 2012 - Optibrium and Cresset Announce Technology Collaboration
Optibrium, a provider of software solutions for drug discovery, and innovative software and services provider Cresset, today announce an agreement to collaborate on the development of next-generation platforms. The innovative companies will work together, combining unique approaches to help drug discovery projects quickly identify novel, potent compounds with a high chance of success downstream. Read press release.
December 29th 2011 - UKTI helps Cambridge firm discover how to boost exports
Discovering a new drug and turning it into a safe product that works is a difficult and very expensive process costing hundreds of millions of pounds, but one Cambridgeshire firm is helping to find the cure, with assistance from UK Trade & Investment (UKTI). Most of the cash spent in the drug discovery process goes on creating and testing compounds that fail. Optibrium, based on the Cambridge Research Park, has come up with some special software to address these issues. StarDrop™ has been on the market since 2005 but the company, which was founded as a spin-out in 2009, have focused on Europe, USA and Japan due to historic relationships. Now, with help from UKTI's Life Sciences Specialist Trade Advisor Claire Lachlan, the company have made in-roads into Singapore, China and India, all huge developing markets. Read press release.
October 18th 2011 - Optibrium Expands StarDrop Availability with Apple Mac Compatibility
Optibrium, a provider of software solutions for drug discovery, today launches StarDrop 5.1, an upgraded version of its innovative support tool which helps drug discovery scientists to guide key decisions in drug discovery and quickly achieve successful project outcomes. As a result of this upgrade, StarDrop's unique capabilities to guide the design and selection of high quality, novel compounds are now available on the Apple Mac, a reflection of the increasing popularity of Macs within the industry. Read press release.
July 19th 2011 - Optibrium Launches New Version of Free StarVue App
Optibrium, a provider of software solutions for drug discovery, today launches a new version of StarVue, its innovative free desktop application that enables scientists to quickly and conveniently view sets of compound structures and related data. The latest version of StarVue can be downloaded free from Optibrium's on-line community. Read press release.
May 23rd 2011 - Optibrium Announces Free Models to Predict Toxicity of Compounds
Optibrium, a provider of software solutions for drug discovery, announces the availability of a range of models to help predict the toxicity of potential new compounds. Optibrium has generated a range of Quantitative Structure Activity Relationship (QSAR) models of key toxicity endpoints, based on data made available by the US Environmental Protection Agency (EPA) as part of its Toxicity Evaluation Software Toolkit (T.E.S.T.). The toxicity prediction models were built with the Auto-Modeller module of the newly launched StarDrop 5 and are available to all StarDrop users free-of-charge. To find out more and download the models please visit Optibrium's on-line community. Read press release.
March 7th 2011 - Optibrium to Unveil StarDrop 5 and Revolutionary Nova Module at ACS Spring 2011
Optibrium, a provider of software solutions for drug discovery, will be officially launching the next generation of StarDrop featuring the ground-breaking Nova module on booth #1121 at the American Chemical Society (ACS) National Exposition, 27th-31st March, 2011, Anaheim, CA. This intuitive platform helps to guide scientists' decisions to quickly identify compounds with a high chance of success for their drug discovery project. Nova is a completely new module within StarDrop 5, helping pharmaceutical and biotech companies to search for high quality drugs by generating new chemistry ideas, prioritised against specific property profile requirements when making critical decisions in drug discovery. Read press release.
January 31st 2011 - Optibrium to Preview New In Silico Drug Discovery Platform at Molecular Med Tri-Conference 2011
Optibrium, a provider of software solutions for drug discovery, will be providing a sneak preview of the next generation of StarDrop at the Molecular Medicine Tri-Conference in San Francisco, CA, 23-25 February, 2011. The exclusive preview of this ground-breaking platform will be available on booth #501, at San Francisco's Moscone North Convention Centre prior to its official launch at the American Chemical Society (ACS) National Exposition, 27-31 March, 2011, Anaheim, CA. StarDrop 5 includes new features focusing on compound idea generation, enhanced visualizations and mathematical data transformations. Read press release.
June 28th 2010 - Optibrium Secures 25 Accounts in First Year of Business
High Profile Client Base Reinforces Optibrium's Commitment to Providing Industry-leading Solutions
Optibrium, a provider of software solutions for drug discovery, today celebrates two significant milestones: its first year of trading and signing its 25th customer. Based in Cambridge, UK, Optibrium has a global customer base ranging from top-ten pharma companies to small biotechs and academic groups, including Johnson & Johnson PR&D, Pfizer, Merck Serono, Teijin Pharma Ltd., Galapagos N.V., MRC Technology, The Campbell Family Institute for Breast Cancer Research and The University of Dundee. Read press release.
February 18th 2010 - Optibrium Showcases StarVue at ACS Spring 2010
Offering an Innovative Free Way to Explore Compound Data for Drug Discovery
Optibrium, a provider of software solutions for drug discovery, will be showcasing StarVue on booth #121 at 2010 Spring ACS National Meeting and Exposition, March 21-25, San Francisco, CA, USA. Optibrium's StarVue is a free desktop application that enables scientists to quickly and conveniently view compound structures and data. The new application eliminates the need to use expensive plug-ins for Microsoft Excel to examine, sort and search chemistry data sets. Visitors to Optibrium's booth #121 at ACS Spring 2010 will receive a copy of StarVue, allowing users to explore their compound data in a new way. Read press release.
February 4th 2010 - Optibrium Unveils StarDrop 4.3
Delivering Enhanced Features to Guide Decisions for Drug Optimisation
Optibrium, a provider of software solutions for drug discovery, today launches StarDrop 4.3. The intuitive software offers advantages over traditional predictive modeling platforms as it specifically helps users to identify chemistries with a high chance of success and focus expensive in-house resources. Used by pharmaceutical and biotech companies and research establishments globally, StarDrop 4.3 guides compound selection and design decisions in all stages of drug discovery. StarDrop 4.3 is the first major update to StarDrop from Optibrium, helping scientists to select high quality drug candidates with confidence, improving efficiency and productivity. Read press release.
November 19th 2009 - Optibrium Launches Online Community for Drug Optimisation
Optibrium today announces the launch of its online community. This provides a rich environment for users of its StarDrop software to interact and gain even more value from this unique platform to guide compound design and selection decisions in drug discovery. The Optibrium community will also provide a forum for the wider drug discovery community to discuss approaches to drug optimisation and share ideas and best practices aimed at improving the productivity of drug discovery. Read press release.
September 22nd 2009 - StarDrop Auto-Modeler Wins Environmental Toxicity Prediction Challenge.
Optibrium successfully demonstrated that its technology for automatically building predictive models of molecule properties can match 'hands-on' modelling approaches by generating the equal-best model in a competition organised by ICANN'09: International Conference on Artificial Neural Networks, European Neural Network Society (ENNS) and CADASTER. The entry by Olga Obrezanova, Principal Scientist at Optibrium, came out joint winner in a challenge to build a model that can predict the environmental toxicity of new molecules. Read press release.
September 15th 2009 - Optibrium and Molecular Networks announce collaboration plans
Optibrium Ltd. and Molecular Networks GmbH today announce plans to further intensify their collaboration and share complementary technology platforms. The companies demonstrated their cooperation with the integration of Molecular Networks' premium 3D structure generator CORINA into StarDrop, Optibrium's intuitive platform for guiding compound selection and design decisions in drug discovery. Read press release.
June 20th 2009 - StarDrop version 4.2.1 released
Optibrium is pleased to announce the first new release of StarDrop since opening for business in May. Version 4.2.1 is a minor upgrade, addressing some of the requests that our users have made for small changes or additions. Along the way, we've also made a few other improvements.
May 20th 2009 - Optibrium opens for business
Based on a management buyout of the StarDrop drug discovery software, Optibrium is dedicated to providing software to guide decisions involving complex, uncertain data in an intuitive way. We'd like to welcome all current and potential StarDrop customers to Optibrium. Read press release.